Galectin Therapeutics (NASDAQ: GALT) has recently received a number of price target changes and ratings updates: 5/25/2022 – Galectin Therapeutics is now covered by analysts at StockNews.com. They set a “sell” rating on the stock. 5/17/2022 – Galectin Therapeutics is now covered by analysts at StockNews.com. They set a “sell” rating on the stock. 5/17/2022 […]
StockNews.com assumed coverage on shares of Galectin Therapeutics (NASDAQ:GALT – Get Rating) in a report issued on Wednesday. The brokerage set a “sell” rating on the stock. Separately, Zacks Investment Research raised shares of Galectin Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, January 19th. NASDAQ:GALT opened at $1.61 […]
StockNews.com initiated coverage on shares of Galectin Therapeutics (NASDAQ:GALT – Get Rating) in a report published on Tuesday. The firm issued a sell rating on the stock. Separately, Zacks Investment Research raised shares of Galectin Therapeutics from a sell rating to a hold rating in a research note on Wednesday, January 19th. Shares of NASDAQ:GALT […]